Last reviewed · How we verify
Nasal Beclomethasone Dipropionate
Beclomethasone dipropionate is a corticosteroid that reduces inflammation in the nasal passages by suppressing immune cell activity and inflammatory mediator release.
Beclomethasone dipropionate is a corticosteroid that reduces inflammation in the nasal passages by suppressing immune cell activity and inflammatory mediator release. Used for Allergic rhinitis, Non-allergic rhinitis, Nasal polyps (adjunctive therapy).
At a glance
| Generic name | Nasal Beclomethasone Dipropionate |
|---|---|
| Also known as | NBDP |
| Sponsor | Stefania La Grutta, MD |
| Drug class | Intranasal corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | FDA-approved |
Mechanism of action
As a topical intranasal corticosteroid, beclomethasone dipropionate binds to glucocorticoid receptors in nasal mucosa, inhibiting the production of pro-inflammatory cytokines and reducing recruitment of inflammatory cells. This decreases nasal inflammation, congestion, and associated symptoms of allergic and non-allergic rhinitis.
Approved indications
- Allergic rhinitis
- Non-allergic rhinitis
- Nasal polyps (adjunctive therapy)
Common side effects
- Headache
- Nasal irritation
- Epistaxis
- Pharyngitis
- Dysgeusia
Key clinical trials
- Directed Topical Drug Delivery for Treatment for PASC Hyposmia (PHASE2)
- To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray (PHASE1, PHASE2)
- Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013) (PHASE3)
- Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161) (PHASE3)
- Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) (PHASE3)
- Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis (PHASE3)
- Personalized Treatment Algorithms for Difficult-to-treat Asthma (PHASE2)
- Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nasal Beclomethasone Dipropionate CI brief — competitive landscape report
- Nasal Beclomethasone Dipropionate updates RSS · CI watch RSS
- Stefania La Grutta, MD portfolio CI